DBV Technologies S.A. (DBVT)
DBVT trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1613780/000162828026021504/0001628280-26-021504-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | DBVT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | France |
| IPO year | 2014 |
| SEC CIK | 0001613780 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | France |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $5.6M |
| Net income | -$146.9M |
| Operating income | -$147.1M |
| Net margin | -2607.3% |
| Operating margin | -2609.2% |
| Revenue growth | +35.8% |
| Cash | $194.2M |
| Total assets | $233.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 114.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Accordingly, substantial doubt exists about the Company's ability to continue as a going concern within twelve months after the date these condensed consolidated financial statements are issued." | 10-Q 2026-10-28 |
| Cash and burn | $165.7M cash; operating cash flow -$47.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 62,877,761 (2026-10-26); 33,822,724 a year earlier; 19,257,711 three years earlier. 3y figure adjusted for split (1-for-2 overall). | Cover page 2026-10-26 |
| Reverse splits, 3 years | 1; latest 1-for-2 on 2024-06-07 | Source 2024-06-07 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-07-27 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Associés, Paris-La Défense, France | PCAOB Form AP 2026-04-29 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $15.5M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.6M | -$64.5M | -$51.5M | $165.7M | $200K | $3.8M | 10-Q 2026-10-28 |
| Q2 2026 2026-06-30 | $700K | -$50.4M | -$52.6M | $174.9M | No debt tags | $5.0M | 10-Q 2026-07-16 |
| Q1 2026 2026-03-31 | $900K | -$47.6M | -$49.1M | $229.2M | No debt tags | $5.8M | 10-Q 2026-04-30 |
| Q4 2025 2025-12-31 | $636K | -$44.8M | -$35.2M | $194.2M | $0 | $5.7M | 10-K 2026-03-26 |
| Q3 2025 2025-09-30 | $2.8M | -$33.2M | -$32.4M | $69.8M | No debt tags | $5.6M | 10-Q 2026-10-28 |
| Q2 2025 2025-06-30 | $1.5M | -$41.9M | -$33.9M | $103.2M | No debt tags | $3.9M | 10-Q 2026-07-16 |
| Q1 2025 2025-03-31 | $800K | -$27.1M | -$19.7M | $13.0M | No debt tags | $3.5M | 10-Q 2026-04-30 |
| Q4 2024 2024-12-31 | $511K | -$23.0M | -$12.3M | $32.5M | No debt tags | $4.2M | 10-K 2026-03-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-07-27 |
| Latest annual report | 10-K/A | 2026-04-30 |
| Latest quarterly / interim | 10-Q | 2026-10-28 |
| Latest current report | 8-K | 2026-10-28 |
| Latest proxy | DEF 14A | 2026-05-11 |
Source: SEC EDGAR submissions feed, 578 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +5.4% |
| 1 month | +22.0% |
| 3 months | -21.5% |
| Year to date | -42.5% |
| 1 year | -15.7% |
| From 52-week high | -55.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BBTX | Bambusa Therapeutics Inc. | $15.98 | -0.68% | $645.4M |
| FDMT | 4D Molecular Therapeutics Inc. | $11.29 | -7.69% | $636.5M |
| ATTO | Attovia Therapeutics Inc. | $14.72 | -2.68% | $673.1M |
| CGEM | Cullinan Therapeutics Inc. | $9.50 | -7.59% | $616.7M |
| SRZN | Surrozen Inc. | $32.32 | +2.25% | $616.1M |
| SLDB | Solid Biosciences Inc. | $6.48 | -5.26% | $723.2M |
| SANA | Sana Biotechnology Inc. | $1.88 | -6.93% | $563.3M |
| IAM | Iambic Therapeutics Inc. | $11.85 | -9.54% | $561.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier